On January 23, 2025, the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin 122 (SAB 122), rescinding the controversial

Cryptocurrency exchange Kraken has brought back blockchain staking offerings for U.S. customers, it said on Thursday, allowing them to lock up their tokens to validate blockchain transactions and earn rewards for doing so.

President Donald Trump has elevated Republican Commissioner Mark Uyeda to take over the SEC from a now-departed Gary Gensler.

The CEOs of Coinbase, Binance and Circle told CNBC they see a clearer path toward getting concrete laws for the crypto industry.

Regulatory authorities continue to advance initiatives to improve the efficiency and sophistication of global securities markets.

U.S. Bancorp, a prominent financial institution, has disclosed in an 8-K filing with the Securities and Exchange Commission the appointment of Gunjan Kedia as the President and Chief Executive Officer,

Coinbase has petitioned the U.S. Second Circuit Court of Appeals to have secondary crypto transactions deemed not securities.  In a Jan. 21 filing, the crypto exchange emphasized that understanding if secondary market crypto transactions are investment contracts under securities laws is of “immense importance to the crypto industry.

Cleary Gottlieb’s Adam Fleisher explains why the securities law framework needs simplification with a new approach to company registration.

The ETFs aim to track 200% of their reference assets' daily performance through swaps, call options, and direct investments.

Reversal of SAB 121 allows banks to offer Bitcoin-backed loans, making it easier for holders to access capital without selling their assets, says BitLab Director Kelly Kellam.

Approximately 9,000 Illinois residents are eligible to claim money from a settlement with investor services company Vanguard after the company was found not to have disclosed the tax implications of a change to its retirement funds.

Jeffrey Eisele, the Chief Development Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.8 billion market cap biopharmaceutical company, recently sold a portion of his holdings in the company.